Additionally, in vitro studies usinghuman GBM cell lines U373–V (−MGMT, +MMR) and U373-M(+MGMT, +MMR) demonstrated synergy among imidazotetrazines (TMZ andits analog: T25) and cannabinoids (CBD and 4′-F-CBD). CBD improved TMZ’s effectiveness in U251and U87MG cell lines and patient-derived GBM163 cells by increasingROS levels, activating the ROS sensor AMP-activated protein kinase(AMPK), and elevating the autophagy marker LC3A. This evidence concerns the gene MAP1LC3A and glioblastoma.